Previous 10 |
home / stock / asclf / asclf news
Deals and Financings Suzhou Innovent Bio (IVBIY) [HK:01801] expanded its 2015 alliance with Eli Lilly (LLY) for Tyvyt ® , Innovent's anti-PD-1 immunotherapy (see story ). In return for a $1+ billion package, Lilly will have an exclusive license to develop Tyvyt in ex-China markets. Lil...
Deals and Financings Shanghai Hansoh Pharma (HK: 3692) obtained Greater China rights to a BCR-ABL inhibitor discovered by Terns Pharma of California. Hansoh will make an upfront payment plus milestones of up to $68 million. It will also pay royalties on sales. TRN-000632 is an investigatio...
COVID-19 Pandemic Sorrento Therapeutics (SRNE), a San Diego-China biotech, reported that its anti-SARS-CoV-2 antibody, STI-1499, completely inhibited SARS-CoV-2 virus infection from interacting with the ACE2 receptor after four days of incubation (see story ). In preclinical studies, the mo...
The outbreak of the novel coronavirus disease COVID-19 rapidly spreads around the globe. The various biotechnology firms, scientists, and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective...
Deals and Financings Leo Pharma, a Denmark dermatology company, acquired global rights to a novel treatment for atopic dermatitis ((AD)) and allergic asthma in an agreement worth up to $570 million. FB825 is a first-in-class candidate that targets the CεmX domain of membrane-bound IgE...
News, Short Squeeze, Breakout and More Instantly...
Ascletis Pharma Inc. Company Name:
ASCLF Stock Symbol:
OTCMKTS Market:
The outbreak of the novel coronavirus disease COVID-19 rapidly spreads around the globe. The various biotechnology firms, scientists, and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective...